Connect with us

International

Undeniable Toxic Ingredients In HPV Vaccines

Undeniable Toxic Ingredients In HPV Vaccines

Authored by Yuhong Dong via The Epoch Times (emphasis ours),

In the series, "The HPV Vaccine:…

Published

on

Undeniable Toxic Ingredients In HPV Vaccines

Authored by Yuhong Dong via The Epoch Times (emphasis ours),

In the series, "The HPV Vaccine: A Double-Edged Sword?" we will provide documented evidence of death and severe injuries linked with Gardasil, analyze the root cause of its harm, and offer solutions.

The Gardasil vaccine is linked to undeniable death and undeniable severe injuries as previously reported in this series of reports. An ingredient in Gardasil may contribute to these harms.

Let's shift the lens to the beautiful Pyrenees in Europe where sheep were cherished for their wool, nourishment, and companionship. However, a mysterious sheep illness occurred around a decade ago.

Mysterious Post-Vaccine Sheep Illness

In August 2006, an outbreak of bluetongue disease quickly spread to European countries causing a state of emergency.

Bluetongue disease, caused by bluetongue virus (BTV), affects ruminants, mainly sheep, with symptoms of fever, hemorrhages, depression, edemas, and generalized cyanosis, easily observed on the tongue, which explains the disease name.

The totally unexpected outbreak caused by a newly emerged BTV serotype led to a massive compulsory European vaccination campaign implemented between 2007 and 2010. The administered vaccine contained a new ingredient not used in previous BTV vaccines—aluminum (Al)—with 2.08 milligrams per milliliter as the adjuvant, in addition to inactivated BTV.

Bluetongue vaccination campaign administered in a sheep farm in Normandy, France, 2008. (Leitenberger Photography/Shutterstock)

The campaign seemed to effectively halt viral spreading, however, during the same vaccination period, a series of previously unreported severe diseases emerged in France, Germany, Switzerland, the UK, and Spain, featuring weakness and various neurological symptoms. Veterinarians were stumped, as no known disease explained the tragedy.

Sheep Study Identifies the Problem

Dr. Lluis Lujan, an associate professor of veterinary pathology at the University of Zaragoza in Spain, conducted a sheep study to determine the cause of the unusual diseases.

A total of 21 sheep were assigned into three groups (red, yellow, and green) with seven in each group as follows:

  1. The red group received commercial sheep vaccines containing aluminum hydroxide.
  2. The yellow group received the equivalent dose of aluminum dissolved in water (Alhydrogel®, an aluminum-based adjuvant).
  3. The green group was administered a neutral saltwater solution.

Surprisingly, both the animals from the red and yellow groups became significantly more aggressive and showed more stereotypes and higher stress.

Sheep from the red and yellow groups became significantly more aggressive. (Illustration by The Epoch Times, Shutterstock)

The detected level of aluminum found in the lymph nodes in the lumbar spinal cord was much higher in both the aluminum-only (yellow) and the vaccine group (red) compared with the control group, indicating that aluminum created an extra burden needing to be processed by the sheep.

This explained the phenomenon that the sheep illness occurred only after the aluminum was added to the vaccine as an adjuvant. "So for me, yes—the reason why the animals get sick after vaccination is how the body deals with aluminum," Dr. Lujan stated in a documentary film "Under the Skin," available on Epoch TV.

The idea is not only about sheep. We are looking for something that could be happening in humans.

'Placebo' Trial Participant Had 40+ Symptoms

The Phase 3 clinical trial for Gardasil (FUTURE II study) began in 2002. A particularly large number of participants were recruited in Denmark.

Gardasil clinical trial participant, Sesilje Petersen, developed severe fatigue and a total of 40 symptoms after the second and third shots.

"It was the biggest problem because I was a student at the university and it was very difficult for me to attend the classes as I fell asleep almost daily," Sesilje said. "I wrote a list with all my symptoms—there were more than 40 symptoms, and some of them had been severe. I had a tumor on my pituitary gland."

"I received a letter and was invited to this study and it sounded very interesting. So I decided to participate," recalled Sesilje.

Sesilje kept the information brochure that the participants received at the beginning of the study. It said that the vaccination had already been carefully tested for safety and did not have any serious side effects.

The information about the placebo turned out to be a lie. "It says here that the placebo was saline—the Danish word for saltwater," she said.

Aluminum: A Toxin in Vaccines for 90 Years

Sesilje's "saline" placebo contained something highly unusual—aluminum (Al), an adjuvant commonly used in modern vaccines.

She was obviously misinformed about the study design and was unaware of what she was receiving. Prior to participating in the Gardasil study, Sesilje knew that she could not tolerate deodorants containing aluminum.

"We were not informed about the use of aluminum. The word aluminum was not given to us either in the procedure or in their phone consent form." Sesilje said.

In fact, a study by Doshi et al. found that participants in the Gardasil trials were not adequately informed that the placebo was amorphous aluminum hydroxyphosphate sulfate (AAHS). The trial participants were told they could receive a "placebo" without being informed of noninert ingredients (AAHS). This raises serious ethical concerns about the trial conduct.

Aluminum was first used in human vaccines in 1932 and was the only adjuvant used in licensed vaccines for approximately 70 years. This controversial compound is still used as an adjuvant in vaccines, however, what is its actual role?

Aluminum is the third most abundant metal in the earth’s crust and is widely present in the environment—in plants, soil, water, air, food, and pharmaceuticals. It is present in an ionic form as Al3+.

The absorption of aluminum depends on several factors such as the pH level and the presence of organic acids (citrate, lactate).  It is absorbed in a proportion of only 0.1 to 0.3 percent by the gastrointestinal tract in the upper intestine.

However, when aluminum is injected into our muscles in the formulation of a vaccine, it is nearly 100 percent absorbed. It then travels and crosses the blood-brain barrier and accumulates in our brain and other organs.

Aluminum is especially harmful to our brain and nerves, as it plays multiple roles in the clumping of harmful substances (β-amyloid, tau protein) in the brain, leads to the death of brain-protective cells called astrocytes, and disrupts the "protective wall" around the brain resulting in more vulnerability to harmful substances.

Christopher Exley, an English professor of bioinorganic chemistry, is one of the most knowledgeable and widely-cited aluminum researchers in the world, with over 200 peer-reviewed scientific papers published on aluminum and over 12,000 citations.

Renal failure patients dialyzed have developed encephalitis linked to excessive brain buildup of aluminum. Those who passed away had a tenfold higher level of aluminum in gray matter, leading to fatal brain diseases in 30 to 50 percent of cases. Their brain symptoms were correlated with their blood aluminum levels, including issues of speech, coordination, cognition, and fatal seizures.

As a potent toxin, aluminum can severely harm multiple human body systems. Aluminum's toxic effects on our nerves, lungs, muscles, gut, kidneys, and liver have been well documented.

Dietary absorbed ionic aluminum can leave our body through the kidneys, however, most antigen-aluminum mixtures in vaccines are too large for the kidneys to expel out of our body. Accordingly, vaccine aluminum exposure poses a much higher safety risk than dietary aluminum.

According to the U.S. Food and Drug Administration (FDA), a placebo is defined as "an inactive pill, liquid, or powder that has no treatment value." The well-established toxic properties of aluminum therefore suggest that aluminum cannot constitute a valid placebo.

Toxicity Makes Aluminum an Adjuvant

Almost all modern diseases have their origin in a disturbed immune system. No other drug intervenes in the immune system as intensively as vaccines. The role of vaccine components in human immunity is discussed without taboos in the scientific community.

The gold standard to evaluate the effectiveness of a vaccine is based on the antibody level generated. In the beginning, people were not satisfied with a pure inactivated virus to provoke an immune response and wanted to find a substance to help boost immunity and generate a more robust response with longer-sustained antibodies—that is the adjuvant.

Aluminum was found to be a strong adjuvant.

According to Mr. Exley, "The known toxicity of aluminum is almost certainly a contributor to the success of aluminum-based salts as adjuvants."

A 2016 Nature study provided insight into the cellular toxicity induced by aluminum used as an adjuvant in clinically-approved human vaccinations.

When we inject a vaccine with aluminum into the muscle, we can only imagine what physical and chemical reactions will be triggered. At the very beginning, there may be little response at the injection site. The only reaction may be due to the damage caused by the needle.

"When the vaccine is injected deeply into the muscle tissue, aluminum ions begin to dissolve and start attacking the surrounding cells," Mr. Exley stated in the documentary "Under the Skin."

"So depending upon that rate of dissolution, you will get the degree of cytotoxicity—cell toxicity," he said.

The aluminum ions kill our normal healthy cells and as those cells die, they release chemical messengers, which call for help from the other immune cells.

Immune cells react immediately and start to attack anything suspicious at the vaccination site. A fierce battle takes place.

It is only in the course of this inflammation triggered by aluminum that the silent antigens are now also taken seriously and are transported away by specialized immune cells. Those silent viral proteins are also identified by immune cells as enemies and specific antibodies are produced to bind them.

Dr. Lluis Lujan in the "Under the Skin" HPV documentary. (Screenshot via The Epoch Times, courtesy of Ehgartner & Moll Filmproduktion GmbH & Co.)
Tyler Durden Sat, 10/14/2023 - 08:10

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

International

Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.

Published

on

Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 

Shutterstock

This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading

Trending